The delay in the HBV program will hurt, but the RSV program may be spared from undue impact. In NASH, my hope is that the ARGON phase-2b trial of EDP-305 will be scrapped entirely, allowing EDP-297 to become the lead NASH compound.
All told, the above doesn't sound as bad as it might have.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.